期刊文献+

全腹腔镜下经胸腔入路治疗Siewert Ⅱ型食管胃结合部腺癌可行性研究 被引量:9

Feasibility study of totally laparoscopic transthoracic approach to treat Siewert Ⅱ adenocarcinoma of the esophagogastric junction
原文传递
导出
摘要 目的探讨全腹腔镜下经胸腔入路治疗Siewert Ⅱ型食管胃结合部腺癌的可行性。方法回顾性分析2017年3-6月吉林大学第二医院胃肠外科行全腹腔镜下经胸腔入路行D2淋巴结清扫和消化道重建的4例Siewert Ⅱ型食管胃结合部腺癌病人的临床资料。均行近端胃切除,并行食管-管状胃消化道重建。结果 4例病人均顺利完成手术,无中转开腹手术。肿物直径为3~5 cm,侵及食管1~3 cm,手术时间为230~370 min,消化道重建时间为40~50 min,术中出血20~90 m L,排气时间为3~4 d,住院时间为8~14 d。无死亡病例,无明显术后并发症发生。随访截至2017-09-01,病人无明显食管反流、进食困难等并发症发生。结论对Siewert Ⅱ型食管胃结合部腺癌行全腹腔镜下经胸腔入路淋巴结清扫和食管-管状胃消化道重建初步疗效观察显示安全可行,值得进一步探索和研究。 Objective To investigate the feasibility of totally laparoscopic transthoracic approach to treat Siewert Ⅱ adenocarcinoma of the esophagogastric junction patients. Methods Clinical and follow-up data of four patients who underwent totally laparoscopic transthoracic approach surgery(proximal gastrectomy, D2 lymph nodes dissection and esophageal-tubular reconstruction) in our department from March to June 2017 were analyzed retrospectively. Results Four patients were successfully completed the operation, no conversion. The size of tumor was 3-5 cm, the length of esophageal invasion was 1-3 cm. The operation time was 230-370 min, the digestive tract reconstruction time was 40-50 min, the volume of intraoperative bleeding was 20-90 mL, the first flatus time was 3-4 d and the hospital stay was 8-14 d. The patients were followed up till 01-09-2017, no obvious esophageal reflux and eating difficulties happened. Conclusion Totally laparoscopic transthoracic approach to treat Siewert Ⅱ adenocarcinoma of the esophagogastric junction patients is safe and feasible.
出处 《中国实用外科杂志》 CSCD 北大核心 2017年第10期1149-1153,共5页 Chinese Journal of Practical Surgery
关键词 全腹腔镜 食管胃结合部腺癌 近端胃切除 经胸腔入路 totally laparoscopic surgery adenocarcinoma of the esophagogastric junction proximal gastrectomy transthoracic approach
  • 相关文献

参考文献1

二级参考文献29

  • 1Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States[J]. Cancer, 1998, 83(10): 2049-2053.
  • 2Buas MF, Vaughan TL. Epidemiology and risk factors for gastro-esophageal junction tumors: understanding the rising incidence of this disease[J]. Semin Radiat Oncol, 2013, 23(1): 3-9.
  • 3Kusano C, Gotoda T, Khor C J, et al. Changing trends in the pro- portion of adenocarcinoma of the esophagogastric junction in a large tertiary referral center in Japan [J]. J Gastroenterol Hepa- tol, 2008, 23(11): 1662-1665.
  • 4Chung JW, Lee GH, Choi KS, et al. Unchanging trend of esopha- gogastric junction adenocareinoma in Korea: experience at a sin- gle institution based on Siewert's classification [J]. Dis Esopha- gus, 2009, 22(8): 676-681.
  • 5Liu K, Yang K, Zhang W, et al. Changes of Esophagogastric Junctional Adenoearcinoma and Gastroesophageal Reflux Dis- ease Among Surgical Patients During 1988-2012: A Single-In- stitution, High-Volume Experience in China [J]. Ann Surg, 2015, [Epub ahead of print].
  • 6Kakeji Y, Yamamoto M, Ito S, et at. Lymph node metastasis from cancer of the esophagogastrie junction, and determination of the appropriate nodal dissection [J]. Surg Today, 2012, 42(4): 351-358.
  • 7Okholm C, Svendsen LB, Aehiam MP. Status and prognosis of lymph node metastasis in patients with eardia cancer - a system- atic review[J]. Surg Oncol, 2014, 23(3): 140-146.
  • 8Pedrazzani C, de Manzoni G, Marrelli D, et at. Lymph node in- volvement in advanced gastroesophageal junction adenoearcino- ma [J]. J Thorac Cardiovasc Surg, 2007, 134(2): 378-385.
  • 9Siewert JR, Stein H J, Feith M. Adenocarcinoma of the esopha- go-gastric junction[J]. Scand J Surg. 2006, 95(4): 260-269.
  • 10Hosokawa Y, Kinoshita T, Konishi M, et at. Clinicopathological features and prognostic factors of adenocarcinoma of the esoph- agogastric junction according to Siewert classification: experi- ences at a single institution in Japan [J]. Ann Surg Oncol, 2012, 19(2): 677-683.

共引文献13

同被引文献59

引证文献9

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部